| Drug discovery considerations in the development of covalent inhibitors R Mah, JR Thomas, CM Shafer Bioorganic & medicinal chemistry letters 24 (1), 33-39, 2014 | 254 | 2014 |
| Design, structure− activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors PA Renhowe, S Pecchi, CM Shafer, TD Machajewski, EM Jazan, C Taylor, ... Journal of medicinal chemistry 52 (2), 278-292, 2009 | 175 | 2009 |
| Indazole benzimidazole compounds PA Renhowe, CM Shafer, C McBride, JB Silver, S Pecchi, ... US Patent 7,064,215, 2006 | 163 | 2006 |
| Quinolinone derivatives PA Renhowe, S Pecchi, TD Machajewski, CM Shafer, C Taylor, ... US Patent 6,605,617, 2003 | 121 | 2003 |
| Mechanism for acivicin inactivation of triad glutamine amidotransferases SV Chittur, TJ Klem, CM Shafer, VJ Davisson Biochemistry 40 (4), 876-887, 2001 | 109 | 2001 |
| Indazole benzimidazole compounds JM Jansen, C McBride, PA Renhowe, C Shafer US Patent 7,642,278, 2010 | 107 | 2010 |
| Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor YS Cho, JR Levell, G Liu, T Caferro, J Sutton, CM Shafer, A Costales, ... ACS Medicinal Chemistry Letters 8 (10), 1116-1121, 2017 | 105 | 2017 |
| Benzimidazole quinolinones and uses thereof PA Barsanti, D Bussiere, SD Harrison, CC Heise, JM Jansen, E Jazan, ... US Patent 7,470,709, 2008 | 97 | 2008 |
| Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors S Ramurthy, S Subramanian, M Aikawa, P Amiri, A Costales, J Dove, ... Journal of medicinal chemistry 51 (22), 7049-7052, 2008 | 92 | 2008 |
| Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers I Aronchik, BA Appleton, SE Basham, K Crawford, M Del Rosario, ... Molecular cancer research 12 (5), 803-812, 2014 | 79 | 2014 |
| Discovery of potent and selective RSK inhibitors as biological probes R Jain, M Mathur, J Lan, A Costales, G Atallah, S Ramurthy, ... Journal of medicinal chemistry 58 (17), 6766-6783, 2015 | 63 | 2015 |
| 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH TR Caferro, YS Cho, AQ Costales, H Lei, F Lenoir, JR Levell, G Liu, ... US Patent 8,957,068, 2015 | 60 | 2015 |
| First total synthesis of bengazole A RJ Mulder, CM Shafer, TF Molinski The Journal of Organic Chemistry 64 (13), 4995-4998, 1999 | 60 | 1999 |
| Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases CM McBride, PA Renhowe, C Heise, JM Jansen, G Lapointe, S Ma, ... Bioorganic & medicinal chemistry letters 16 (13), 3595-3599, 2006 | 55 | 2006 |
| Substituted benz-azoles and methods of their use as inhibitors of Raf kinase PA Renhowe, S Ramurthy, P Amiri, BH Levine, DJ Poon, S Subramanian, ... US Patent 7,071,216, 2006 | 53 | 2006 |
| Quinolinone derivatives PA Renhowe, S Pecchi, TD Machajewski, CM Shafer, C Taylor, ... US Patent 6,774,237, 2004 | 50 | 2004 |
| Monosubstituted oxazoles. 1. synthesis of 5-substituted oxazoles by directed alkylation CM Shafer, TF Molinski The Journal of Organic Chemistry 63 (3), 551-555, 1998 | 50 | 1998 |
| Discovery of RAF265: a potent mut-B-RAF inhibitor for the treatment of metastatic melanoma TE Williams, S Subramanian, J Verhagen, CM McBride, A Costales, ... ACS medicinal chemistry letters 6 (9), 961-965, 2015 | 49 | 2015 |
| Oxidative Rearrangement of 2-Substituted Oxazolines. A Novel Entry to 5,6-Dihydro-2H-1,4-oxazin-2-ones and Morpholin-2-ones CM Shafer, TF Molinski The Journal of Organic Chemistry 61 (6), 2044-2050, 1996 | 48 | 1996 |
| 4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors CM Shafer, M Lindvall, C Bellamacina, TG Gesner, A Yabannavar, W Jia, ... Bioorganic & medicinal chemistry letters 18 (16), 4482-4485, 2008 | 43 | 2008 |
